Home Protein Tyrosine Kinase Tie-2

Tie-2

Tie-2 Products

  • All (6)
  • Tie-2 Inhibitors (4)
  • Tie-2 Antibodies (2)
  • New Tie-2 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1361 MGCD-265 analog MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cell Rep Med, 2022, 3(1):100492
Protein Cell, 2019, 10(3):161-177
S1577 Tie2 kinase inhibitor 1 Tie2 kinase inhibitor 1 is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38.
Front Pharmacol, 2024, 15:1290128
Protein Cell, 2023, 14(5):350-368
Cancer Lett, 2022, S0304-3835(22)00005-2
S7799 Pexmetinib Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
J Bone Oncol, 2022, 35:100439
Theranostics, 2021, 11(4):1626-1640
Sci Rep, 2021, 11(1):5752
S6412 Altiratinib Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.
Theranostics, 2021, 11(20):9918-9936
Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
A2725 Anti-TIE2 / CD202b Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD.
A2771 Zansecimab (Anti-ANGPT2) Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD.
S1361 MGCD-265 analog MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cell Rep Med, 2022, 3(1):100492
Protein Cell, 2019, 10(3):161-177
S1577 Tie2 kinase inhibitor 1 Tie2 kinase inhibitor 1 is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38.
Front Pharmacol, 2024, 15:1290128
Protein Cell, 2023, 14(5):350-368
Cancer Lett, 2022, S0304-3835(22)00005-2
S7799 Pexmetinib Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
J Bone Oncol, 2022, 35:100439
Theranostics, 2021, 11(4):1626-1640
Sci Rep, 2021, 11(1):5752
S6412 Altiratinib Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.
Theranostics, 2021, 11(20):9918-9936
Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
A2725 Anti-TIE2 / CD202b Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD.
A2771 Zansecimab (Anti-ANGPT2) Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD.

Choose Selective Tie-2 Inhibitors

Tie-2Signaling Pathway

Tie-2信号通路图
Tags: Tie-2 signaling | TEK kinase activty | Tie-2 kinase activty | Tie-2 pathway | Tie-2 phosphorylation | Tie2 signaling pathway | Tie-2 inhibitor review